$APRE
Aprea Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024011806 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $354.6K $561.6K $249.7K
YoY Change 10.82% 124.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.605M $1.851M $1.699M
YoY Change -6.67% 8.95% -89.13%
% of Gross Profit
Research & Development $2.846M $2.558M $2.203M
YoY Change 34.1% 16.12% -67.66%
% of Gross Profit
Depreciation & Amortization $5.430K $5.300K $220.00
YoY Change 2309.09% -94.1%
% of Gross Profit
Operating Expenses $4.452M $4.408M $3.901M
YoY Change 15.86% 13.0% -96.04%
Operating Profit -$4.097M -$3.847M -$3.652M
YoY Change 16.3% 5.35% -96.29%
Interest Expense $348.7K $382.4K $336.2K
YoY Change 8.57% 13.73% 540.53%
% of Operating Profit
Other Income/Expense, Net $313.2K $376.9K $392.6K
YoY Change -1.6% -4.0% 89.6%
Pretax Income -$3.784M -$3.470M -$3.259M
YoY Change 18.24% 6.47% -96.68%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.784M -$3.470M -$3.259M
YoY Change 18.08% 6.47% -96.68%
Net Earnings / Revenue -1066.99% -617.92% -1305.26%
Basic Earnings Per Share -$0.64 -$0.58 -$0.87
Diluted Earnings Per Share -$0.64 -$0.58 -$0.87
COMMON SHARES
Basic Shares Outstanding 5.432M 5.430M 3.732M
Diluted Shares Outstanding 5.940M 5.937M 3.732M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.25M $28.69M $27.69M
YoY Change 3.35% 3.65% -29.13%
Cash & Equivalents $26.20M $28.70M $27.69M
Short-Term Investments
Other Short-Term Assets $234.2K $865.1K $953.7K
YoY Change -21.93% -9.29% -31.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.48M $29.56M $28.64M
YoY Change 3.29% 3.22% -29.22%
LONG-TERM ASSETS
Property, Plant & Equipment $86.95K $92.38K $1.687K
YoY Change 0.87% 5375.93% -91.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $281.7K $271.2K $40.18K
YoY Change 574.87% 36.86%
Total Long-Term Assets $410.1K $404.8K $41.87K
YoY Change 223.85% 866.87% -81.02%
TOTAL ASSETS
Total Short-Term Assets $26.48M $29.56M $28.64M
Total Long-Term Assets $410.1K $404.8K $41.87K
Total Assets $26.89M $29.96M $28.68M
YoY Change 4.38% 4.48% -29.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.154M $964.3K $1.131M
YoY Change 33.78% -14.75% -71.65%
Accrued Expenses $2.482M $2.079M $2.820M
YoY Change -24.79% -26.26% -23.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.636M $3.094M $3.951M
YoY Change -12.73% -21.68% -48.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.636M $3.094M $3.951M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.636M $3.094M $3.951M
YoY Change -13.43% -21.68% -48.59%
SHAREHOLDERS EQUITY
Retained Earnings -$318.1M -$314.4M -$301.4M
YoY Change 4.43% 4.29% 4.91%
Common Stock $5.435K $5.430K $3.731K
YoY Change 45.48% 45.54% -84.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.95M $25.56M $23.42M
YoY Change
Total Liabilities & Shareholders Equity $26.89M $29.96M $28.68M
YoY Change 4.38% 4.48% -29.5%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.784M -$3.470M -$3.259M
YoY Change 18.08% 6.47% -96.68%
Depreciation, Depletion And Amortization $5.430K $5.300K $220.00
YoY Change 2309.09% -94.1%
Cash From Operating Activities -$2.468M -$3.642M -$3.217M
YoY Change 10.19% 13.2% -63.87%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $7.500K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$7.500K
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.160K -21.06K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.468M -3.642M -3.217M
Cash From Investing Activities 0.000 -7.500K
Cash From Financing Activities -1.160K -21.06K 0.000
Net Change In Cash -2.469M -3.670M -3.217M
YoY Change 5.99% 14.09% -63.87%
FREE CASH FLOW
Cash From Operating Activities -$2.468M -$3.642M -$3.217M
Capital Expenditures $0.00 $7.500K
Free Cash Flow -$2.468M -$3.649M
YoY Change 5.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001781983
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5430215
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3736673
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
apre Lessee Operating Lease Annual Base Rent Obligation After Current Year
LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39069
dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
dei Entity Address Address Line1
EntityAddressAddressLine1
3805 Old Easton Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Doylestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18902
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
463-9385
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
APRE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5431903
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28694694
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21606820
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
865092
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
914275
CY2024Q2 us-gaap Assets Current
AssetsCurrent
29559786
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22521095
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92379
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88362
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
41260
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
40717
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
271162
CY2024Q2 us-gaap Assets
Assets
29964587
CY2023Q4 us-gaap Assets
Assets
22650174
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
964327
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1670369
CY2024Q2 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2079163
CY2023Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2186262
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
50739
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
528974
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3094229
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4385605
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5430215
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3736673
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
5430
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3736
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
350545473
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
335644204
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10628304
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10611273
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314363304
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308083161
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
25559295
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16953506
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29964587
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22650174
CY2024Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
561574
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
249688
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
942143
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
249688
CY2024Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2557679
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2202657
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4158052
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3459199
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1850819
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1698712
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3780685
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5064673
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
4408498
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3901369
us-gaap Operating Expenses
OperatingExpenses
7938737
us-gaap Operating Expenses
OperatingExpenses
8523872
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3846924
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3651681
us-gaap Operating Income Loss
OperatingIncomeLoss
-6996594
us-gaap Operating Income Loss
OperatingIncomeLoss
-8274184
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
382374
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
336221
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
665777
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
592631
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5502
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
56363
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
50674
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42566
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
376872
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
392584
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
716451
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
635197
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3470052
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3259097
us-gaap Net Income Loss
NetIncomeLoss
-6280143
us-gaap Net Income Loss
NetIncomeLoss
-7638987
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1948
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73420
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17031
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11464
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3472000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3332517
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6297174
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7650451
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5937291
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5937291
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3731571
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3731571
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5067809
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5067809
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3497329
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3497329
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4871865
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16244
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61956
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4379890
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26481978
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
269323
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73420
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3259097
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23418784
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16953506
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14709705
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85830
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15083
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2810091
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
28923867
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21060
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
128488
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1948
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3470052
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
25559295
us-gaap Profit Loss
ProfitLoss
-6280143
us-gaap Profit Loss
ProfitLoss
-7638987
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11461
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
634
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
214318
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
285567
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
50674
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42566
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
223296
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-410246
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-703473
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
289605
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-67470
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
499516
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-478235
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7577512
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6195985
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15478
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15478
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15999598
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5788918
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1310953
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
648928
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14688645
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5139990
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7095655
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1055995
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-7238
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-5341
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21647537
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28735954
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27725311
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28694694
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27685131
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
41260
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
40180
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28735954
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27725311
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
41000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2998161
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
612225
CY2024Q2 apre Lessee Operating Lease Number Of Operating Leases
LesseeOperatingLeaseNumberOfOperatingLeases
1
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
19997
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
19997
us-gaap Operating Lease Expense
OperatingLeaseExpense
39995
us-gaap Operating Lease Expense
OperatingLeaseExpense
39995
apre Lessee Operating Lease Annual Base Rent
LesseeOperatingLeaseAnnualBaseRent
110000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
209372
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138601
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
582437
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016960
CY2024Q2 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
1240751
CY2023Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
856575
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46603
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
174126
CY2024Q2 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2079163
CY2023Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2186262
CY2024Q2 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
28112
apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
128488
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
269323
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
214318
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
285567
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001558370-24-011806-index-headers.html Edgar Link pending
0001558370-24-011806-index.html Edgar Link pending
0001558370-24-011806.txt Edgar Link pending
0001558370-24-011806-xbrl.zip Edgar Link pending
apre-20240630.xsd Edgar Link pending
apre-20240630x10q.htm Edgar Link pending
apre-20240630xex31d1.htm Edgar Link pending
apre-20240630xex31d2.htm Edgar Link pending
apre-20240630xex32d1.htm Edgar Link pending
apre-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
apre-20240630_cal.xml Edgar Link unprocessable
apre-20240630_def.xml Edgar Link unprocessable
apre-20240630_lab.xml Edgar Link unprocessable
apre-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apre-20240630x10q_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending